Health status of White Americans

Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND

Retrieved on: 
Friday, December 10, 2021

Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics, presented an analysis of the baseline characteristics of the first 27 patients enrolled in COURAGE-ALS.

Key Points: 
  • Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics, presented an analysis of the baseline characteristics of the first 27 patients enrolled in COURAGE-ALS.
  • COURAGE-ALS is a Phase 3, multi-center, double-blind, randomized, placebo-controlled trial of reldesemtiv expected to enroll approximately 555 patients with ALS.
  • Key inclusion criteria in COURAGE-ALS include symptom onset within 24 months and ALS Functional Rating Scale-Revised (ALSFRS-R) total score of 44.
  • For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.

Decision Point Partners with Hyperlift to Amplify Medicare Star Improvement

Retrieved on: 
Wednesday, December 8, 2021

Under this partnership, Medicare Advantage plans can leverage the solutions from both companies to impact Medicare Star performance with speed and accuracy.

Key Points: 
  • Under this partnership, Medicare Advantage plans can leverage the solutions from both companies to impact Medicare Star performance with speed and accuracy.
  • Using Hyperlifts Star Management Suite, Medicare Advantage plans can:
    Track Star measure performance & drive action at a daily, weekly, or monthly cadence.
  • Mr. Saeed Aminzadeh, Chief Executive Officer of Decision Point said, "Several of our clients have been using Hyperlift to strategically focus their efforts for maximum performance gain.
  • It only made sense that Hyperlift and Decision Point join forces to provide a complete solution to Medicare Advantage plans.

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

Retrieved on: 
Monday, December 6, 2021

ODD is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases or conditions.

Key Points: 
  • ODD is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases or conditions.
  • Longeveron recently reported clinical results from its safety-focused Phase 1 clinical study of Lomecel-B in HLHS patients.
  • Longeveron is currently enrolling ELPIS II, a 38-subject, Phase 2 randomized, double-blind, controlled clinical trial examining the effect of Lomecel-B in HLHS affected infants.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).

iDirect Government Debuts Evolution Defense 4.4 Software with Enhanced Security

Retrieved on: 
Tuesday, November 30, 2021

Evolution Defense 4.4 technology advancements are targeted at the DLC-R line cards, enabling Communication Signal Interference Removal (CSIR) on the DLC-R line cards, and other security improvements.

Key Points: 
  • Evolution Defense 4.4 technology advancements are targeted at the DLC-R line cards, enabling Communication Signal Interference Removal (CSIR) on the DLC-R line cards, and other security improvements.
  • CSIR represents a real-time streaming technology to mitigate interference, and the introduction of Evolution Defense 4.4 now applies to both iDirectGovs remote and line cards.
  • This release complements the previous Evolution Defense 4.2.2.0 software release, which provided CSIR protection on the 9-Series, establishing a complete end-to-end interference mitigation solution.
  • With security a highest priority for iDirectGov, the Evolution Defense platform is continuously tested and evaluated to ensure mission critical data is protected.

United Kingdom m-Health App Market Report 2021 Featuring Yecco, Emis Group, Ampersand & Ampersand, Handle My Health, Philips Healthcare, Apple, Medtronic - ResearchAndMarkets.com

Retrieved on: 
Monday, November 29, 2021

The "United Kingdom m-Health App Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United Kingdom m-Health App Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The United Kingdom m-Health app market is projected to grow at a CAGR of 22.43% to reach US$1,111.589 million by 2026 from US$269.568 million in 2019.
  • The United Kingdom performs relatively well in almost all the measures of well-being as compared to the other countries in the better life index.
  • According to Oxford University, The National Health Service's digital tracing smartphone app has been downloaded onto more than 21 million UK devices.

Pendella-HealthEE Partnership Closes the Protection Gap Bringing Individual Life and Disability Insurance to Hundreds of Thousands of Americans

Retrieved on: 
Tuesday, November 23, 2021

Through Pendella's AI-powered enterprise SaaS solution, customers can easily buy an individual life and disability insurance policy all within a browser in minutes.

Key Points: 
  • Through Pendella's AI-powered enterprise SaaS solution, customers can easily buy an individual life and disability insurance policy all within a browser in minutes.
  • "HealthEE is on a mission to bring important health and life insurance protection to underserved middle-income Americans," said Bob Gaydos, CEO of Pendella.
  • "This partnership is another step towards closing the protection gap and creating greater financial security for hundreds of thousands of families."
  • "The Pendella-HealthEE partnership will empower our end users to make life and disability accessible and affordable," said Christian Stearns, CEO of HealthEE.

Study Shows Health Benefits from Membership at a Medical Fitness Facility

Retrieved on: 
Wednesday, November 10, 2021

The studywas conducted over a ten-year period from 2005 to 2015 with two certified medical fitness facilities, The Wellness Institute and Reh-Fit Centre in Winnipeg, Manitoba, to look at the link between membership at a medical fitness facility and health outcomes.

Key Points: 
  • The studywas conducted over a ten-year period from 2005 to 2015 with two certified medical fitness facilities, The Wellness Institute and Reh-Fit Centre in Winnipeg, Manitoba, to look at the link between membership at a medical fitness facility and health outcomes.
  • The medical fitness modelis designed to improve health status by providing evidence-based, medically integrated programming to promote health.
  • Unlike traditional fitness facilities, this model incorporates medical oversight; clinical integration with a health system; a higher level of staff education and training; health assessments; and health education.
  • "We are pleased to see the validation of what we have seen in the growing medical fitness industry,"said David Flench, CEO of the Medical Fitness Association.

Improving Hospice and Palliative Care for Patients, VITAS® Healthcare Launches Opioid Dosage Conversion Tool

Retrieved on: 
Tuesday, November 9, 2021

MIAMI, Nov. 9, 2021 /PRNewswire/ -- Today, VITAS Healthcare, the nation's leading provider of end-of-life care, launched the industry's first comprehensive opioid conversion tool.

Key Points: 
  • MIAMI, Nov. 9, 2021 /PRNewswire/ -- Today, VITAS Healthcare, the nation's leading provider of end-of-life care, launched the industry's first comprehensive opioid conversion tool.
  • Introduced during National Hospice and Palliative Care Month, the newest feature of the award-winning VITAS mobile app is designed for patients with advanced illness.
  • Healthcare professionals caring for patients eligible for hospice and palliative care can use the tool to prescribe opioids, manage pain effectively and respect the unique needs of patients nearing the end of life.
  • The opioid converter is the latest feature available in the VITAS Healthcare mobile app, a free platform for healthcare professionals seeking accurate, easy-to-use hospice information to support prognostication.

Pendella-Execupay Partnership Brings Important Financial Protection to 1.3 Million Small Business Employees

Retrieved on: 
Friday, November 5, 2021

Through Pendella's AI-powered enterprise SaaS solution, employees can easily buy an individual life and disability insurance policy all within a browser in minutes.

Key Points: 
  • Through Pendella's AI-powered enterprise SaaS solution, employees can easily buy an individual life and disability insurance policy all within a browser in minutes.
  • "Our partnership with Execupay empowers small business owners to bring the single-most-important financial protection to their employees without requiring any additional costs or resources," said Bob Gaydos, CEO of Pendella.
  • "Together, we are closing the protection gap and creating greater financial security for future generations."
  • "This is an opportunity for small business owners to deliver important financial protection their employees want and need."

Digital Medicine Society Convenes Pharmaceutical Leaders to Collaborate on New Digital Endpoint

Retrieved on: 
Tuesday, November 2, 2021

DiMe believes that digital endpoints present an opportunity to provide a more meaningful and complete understanding of patients' conditions and responses.

Key Points: 
  • DiMe believes that digital endpoints present an opportunity to provide a more meaningful and complete understanding of patients' conditions and responses.
  • This initiative is laser-focused on bringing a well-developed digital measure to bear as a broadly accepted digital endpoint for use in medical product development.
  • About the Digital Medicine Society: The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community, driving scientific progress and broad acceptance of digital medicine to enhance public health.
  • At DiMe, our commitment to fully integrating experts from all of the disciplines comprising digital medicine is unwavering.